Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects

Abstract

This paper reviews melatonin as an overlooked factor in the developmental etiology and maintenance of schizophrenia; the neuroimmune and oxidative pathophysiology of schizophrenia; specific symptoms in schizophrenia, including sleep disturbance; circadian rhythms; and side effects of antipsychotics, including tardive dyskinesia and metabolic syndrome. Electronic databases, i.e. PUBMED, Scopus and Google Scholar were used as sources for this review using keywords: schizophrenia, psychosis, tardive dyskinesia, antipsychotics, metabolic syndrome, drug side effects and melatonin. Articles were selected on the basis of relevance to the etiology, course and treatment of schizophrenia. Melatonin levels and melatonin circadian rhythm are significantly decreased in schizophrenic patients. The adjunctive use of melatonin in schizophrenia may augment the efficacy of antipsychotics through its anti-inflammatory and antioxidative effects. Further, melatonin would be expected to improve sleep disorders in schizophrenia and side effects of anti-psychotics, such as tardive dyskinesia, metaboilic syndrome and hypertension. It is proposed that melatonin also impacts on the tryptophan catabolic pathway via its effect on stress response and cortisol secretion, thereby impacting on cortex associated cognition, amygdala associated affect and striatal motivational processing. The secretion of melatonin is decreased in schizophrenia, contributing to its etiology, pathophysiology and management. Melatonin is likely to have impacts on the metabolic side effects of anti-psychotics that contribute to subsequent decreases in life-expectancy.

This is a preview of subscription content, access via your institution.

References

  1. Afonso P, Brissos S, Figueira ML, Paiva T (2010) Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep. Schizophr Res 120(1–3):227–228

    PubMed  CAS  Google Scholar 

  2. Afonso P, Brissos S, Figueira ML, Paiva T (2011a) Schizophrenia patients with predominantly positive symptoms have more disturbed sleep-wake cycles measured by actigraphy. Psychiatry Res 189(1):62–66

    PubMed  Article  Google Scholar 

  3. Afonso P, Figueira ML, Paiva T (2011b) Sleep-promoting action of the endogenous melatonin in schizophrenia compared to healthy controls. Int J Psychiatry Clin Pract 15(4):311–315

    PubMed  Article  CAS  Google Scholar 

  4. Alonso-Vale MI, Peres SB, Vernochet C, Farmer SR, Lima FB (2009) Adipocyte differentiation is inhibited by melatonin through the regulation of C/EBPbeta transcriptional activity. J Pineal Res 47(3):221–227

    PubMed  Article  CAS  Google Scholar 

  5. Anderson G (2011) Neuronal-immune interactions in mediating stress effects in the etiology and course of schizophrenia: role of the amygdala in developmental co-ordination. Med Hypotheses 76(1):54–60

    PubMed  Article  Google Scholar 

  6. Anderson G, Ojalla J (2010) Alzheimer’s and seizures: interleukin-18, indoleamine 2,3-Dioxygenase and quinolinic acid. Int J Tryp Res 3:169–173

    Article  CAS  Google Scholar 

  7. Aufdenblatten M, Baumann M, Raio L, Dick B, Frey BM, Schneider H, Surbek D, Hocher B, Mohaupt MG (2009) Prematurity is related to high placental cortisol in preeclampsia. Pediatr Res 65(2):198–202

    PubMed  Article  CAS  Google Scholar 

  8. Aversa S, Pellegrino S, Barberi I, Reiter RJ, Gitto E (2012) Potential utility of melatonin as an antioxidant during pregnancy and in the perinatal period. J Matern-Fetal Neonatal Med 25(3):207–221

    PubMed  CAS  Google Scholar 

  9. Bersani G, Mameli M, Garavini A, Pancheri P, Nordio M (2003) Reduction of night/day difference in melatonin blood levels as a possible disease-related index in schizophrenia. Neuro Endocrinol Lett 24(3–4):181–184

    PubMed  CAS  Google Scholar 

  10. Bikle DD (2009) Vitamin D and immune function: understanding common pathways. Curr Osteoporos Rep 7(2):58–63

    PubMed  Article  Google Scholar 

  11. Bošković M, Vovk T, Kores Plesničar B, Grabnar I (2011) Oxidative stress in schizophrenia. Curr Neuropharmacol 9(2):301–312

    PubMed  Article  Google Scholar 

  12. Brown AS, Derkitis EJ (2010) Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 167(3):261–280

    PubMed  Article  Google Scholar 

  13. Bushe CJ, Leonard BE (2007) Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 68(11):1682–1690

    PubMed  Article  CAS  Google Scholar 

  14. Byrne M, Agerbo E, Bennedsen B, Eaton WW, Mortensen PB (2007) Obstetric conditions and risk of first admission with schizophrenia: a Danish national register based study. Schizophr Res 97(1–3):51–59

    PubMed  Article  Google Scholar 

  15. Cantó C, Auwerx J (2009) Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab 20(7):325–331

    PubMed  Article  Google Scholar 

  16. Causevic M, Mohaupt M (2007) 11beta-Hydroxysteroid dehydrogenase type 2 in pregnancy and preeclampsia. Mol Aspects Med 28(2):220–226

    PubMed  Article  CAS  Google Scholar 

  17. Chang HM, Wu UI, Lan CT (2009) Melatonin preserves longevity protein (sirtuin 1) expression in the hippocampus of total sleep-deprived rats. J Pineal Res 47(3):211–220

    PubMed  Article  CAS  Google Scholar 

  18. Chun RF, Adams JS, Hewison M (2008) Review: Back to the future: a new look at “old” vitamin D3. J Endocrinol 198:261–269

    PubMed  Article  CAS  Google Scholar 

  19. Chwastiak LA, Tek C (2009) The unchanging mortality gap for people with schizophrenia. Lancet 374(9690):590–592

    PubMed  Article  Google Scholar 

  20. Condray R, Dougherty GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK (2011) 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 14:756–767

    PubMed  Article  CAS  Google Scholar 

  21. Drexhage RC, Hoogenboezem TA, Cohen D, Versnel MA, Nolen WA, van Beverens NJM, Drexhage HA (2011) An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol 14:746–755

    PubMed  Article  CAS  Google Scholar 

  22. Esposito E, Cuzzocrea S (2010) Antiinflammatory activity of melatonin in central nervous system. Curr Neuropharmacol 8(3):228–242

    PubMed  Article  CAS  Google Scholar 

  23. Evans KN, Nguyen L, Chan J, Innes BA, Bulmer JN, Kilby MD, Hewison M (2006) Effects of 25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on cytokine production by human decidual cells. Biol Reprod 75(6):816–822

    PubMed  Article  CAS  Google Scholar 

  24. Flaum M (2010) Strategies to close the “mortality gap”. Am J Psychiatry 167(2):120–121

    PubMed  Article  Google Scholar 

  25. Graham SM, Howgate D, Anderson W, Howes C, Heliotis M, Mantalaris A, Tsiridis E, Tsapakis E (2011) Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf 10(4):575–602

    PubMed  Article  CAS  Google Scholar 

  26. Grant WB (2010) Low vitamin D may explain the link between preeclampsia and cardiovascular disease. Am Heart J 159(3):e19

    PubMed  Article  Google Scholar 

  27. Holmes VA, Barnes MS, Alexander HD, McFaul P, Wallace JM (2009) Vitamin D deficiency and insufficiency in pregnant women: a longitudinal study. Br J Nutr 102(6):876–881

    PubMed  Article  CAS  Google Scholar 

  28. Jiang HK, Wang JY (1998) Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients. J Formos Med Assoc 97(12):830–837

    PubMed  CAS  Google Scholar 

  29. Kilzieh N. Principal investigator. ClinicalTrials.gov Identifier: NCT00512070

  30. Kim YK, Myint AM, Verkerk R, Scharpe S, Steinbusch H, Leonard B (2009) Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 59:123–129

    PubMed  Article  CAS  Google Scholar 

  31. Kristo C, Godang K, Ueland T, Lien E, Aukrust P, Froland SS, Bollerslev J (2002) Raised serum levels of interleukin-8 and interleukin-18 in relation to bone metabolism in endogenous Cushing’s syndrome. Eur J Endocrinol 146(3):389–395

    PubMed  Article  CAS  Google Scholar 

  32. Kuo CJ, Yang SY, Liao YT, Chen WJ, Lee WC, Shau WY, Chang YT, Tsai SY, Chen CC (in press) Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull

  33. Lanoix D, Beghdadi H, Lafond J, Vaillancourt C (2008) Human placental trophoblasts synthesize melatonin and express its receptors. J Pineal Res 45(1):50–60

    PubMed  Article  CAS  Google Scholar 

  34. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR (2010) Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 210(1):84–91

    PubMed  Article  CAS  Google Scholar 

  35. Lee YD, Kim JY, Lee KH, Kwak YJ, Lee SK, Kim OS, Song DY, Lee JH, Baik TK, Kim BJ, Kim JY, Baik HW (2009) Melatonin attenuates lipopolysaccharide-induced acute lung inflammation in sleep-deprived mice. J Pineal Res 46(1):53–57

    PubMed  Article  Google Scholar 

  36. Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ (2011) Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology 16(4):611

    PubMed  Article  Google Scholar 

  37. Lerner V, Miodownik C (2011) Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment. Curr Psychiatry Rep 13(4):295–304

    PubMed  Article  Google Scholar 

  38. Luchowska E, Kloc R, Olajossy B, Wnuk S, Wielosz M, Owe-Larsson B, Urbanska EM (2009) Beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiatry 33(3):519–529

    PubMed  Article  CAS  Google Scholar 

  39. Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89:346–351

    PubMed  Article  CAS  Google Scholar 

  40. Maldonado MD, Pérez-San-Gregorio MA, Reiter RJ (2009a) The role of melatonin in the immuno-neuro-psychology of mental disorders. Recent Pat CNS Drug Discov 4(1):61–69

    PubMed  Article  CAS  Google Scholar 

  41. Maldonado MD, Reiter RJ, Pérez-San-Gregorio MA (2009b) Melatonin as a potential therapeutic agent in psychiatric illness. Hum Psychopharmacol 24(5):391–400

    PubMed  Article  CAS  Google Scholar 

  42. Mann K, Rossbach W, Müller MJ, Müller-Siecheneder F, Pott T, Linde I, Dittmann RW, Hiemke C (2006) Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. Psychoneuroendocrinology 31(2):256–264

    PubMed  Article  CAS  Google Scholar 

  43. Marczynski TJ, Yamaguchi N, Ling GM, Grodzinska L (1964) Sleep induced by the administration of melatonin (5-methoxyn-acetyltryptamine) to the hypothalamus in unrestrained cats. Experientia 20(8):435–437

    PubMed  Article  CAS  Google Scholar 

  44. Martín M, Macías M, León J, Escames G, Khaldy H, Acuña-Castroviejo D (2002) Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 34(4):348–357

    PubMed  Article  Google Scholar 

  45. Marzullo G, Fraser FC (2009) Conception season and cerebral asymmetries among American baseball players: implications for the seasonal birth effect in schizophrenia. Psychiatry Res 167(3):287–293

    PubMed  Article  Google Scholar 

  46. McGrath J, Eyles D, Mowry B, Yolken R, Buka S (2003) Low maternal vitamin D as a risk factor for schizophrenia: a pilot study using banked sera. Schizophr Res 63(1–2):73–78

    PubMed  Article  Google Scholar 

  47. Meyer U, Feldon J, Dammann O (2011) Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 69(5 Pt 2):26R–33R

    PubMed  Article  Google Scholar 

  48. Miller J, Gallo RL (2010) Vitamin D and innate immunity. Dermatol Ther 23(1):13–22

    PubMed  Article  Google Scholar 

  49. Miller CL, Llenos IC, Dulay JR, Weis S (2006) Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 1073–1074:25–37

    PubMed  Article  Google Scholar 

  50. Miller CL, Murakami P, Ruczinski I, Ross RG, Sinkus M, Sullivan B, Leonard S (2009) Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res 113(2–3):259–267

    PubMed  Article  Google Scholar 

  51. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663–671

    PubMed  Article  CAS  Google Scholar 

  52. Monteleone P, Maj M, Fusco M, Kemali D, Reiter RJ (1992) Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Schizophr Res 7(1):77–84

    PubMed  Article  CAS  Google Scholar 

  53. Monteleone P, Natale M, La Rocca A, Maj M (1997) Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Neuropsychobiology 36(4):159–163

    PubMed  Article  CAS  Google Scholar 

  54. Myint AM, Schwarz MJ, Verkerk R, Mueller HH, Zach J, Scharpé S, Steinbusch HW, Leonard BE, Kim YK (2011) Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients. Brain Behav Immun 25(8):1576–1581

    PubMed  Article  CAS  Google Scholar 

  55. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, Wang L, Zhang C, Lin X, Zhang G, Arendash GW (2009) Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 47(1):82–96

    PubMed  Article  CAS  Google Scholar 

  56. Park HJ, Park JK, Kim SK, Cho AR, Kim JW, Yim SV, Chung JH (2011) Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci 45(2):304–308

    PubMed  Article  CAS  Google Scholar 

  57. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63:801–808

    PubMed  Article  CAS  Google Scholar 

  58. Praschak-Rieder N, Willeit M, Wilson AA, Houle S, Meyer JH (2008) Seasonal variation in human brain serotonin transporter binding. Arch Gen Psychiatry 65(9):1072–1078

    PubMed  Article  Google Scholar 

  59. Proietti S, Cucina A, D’Anselmi F, Dinicola S, Pasqualato A, Lisi E, Bizzarri M (2011) Melatonin and vitamin D3 synergistically down-regulate Akt and MDM2 leading to TGFβ-1-dependent growth inhibition of breast cancer cells. J Pineal Res 50(2):150–158

    PubMed  CAS  Google Scholar 

  60. Quiros I, Mayo JC, Garcia-Suarez O, Hevia D, Martin V, Rodríguez C, Sainz RM (2008) Melatonin prevents the glucocorticoid receptor inhibition of cell proliferation and toxicity in hippocampal cells by reducing the glucocorticoid receptor nuclear translocation. J Steroid Biochem Mol Biol 110:116–124

    PubMed  Article  CAS  Google Scholar 

  61. Rao ML, Gross G, Strebel B, Halaris A, Huber G, Bräunig P, Marler M (1994) Circadian rhythm of tryptophan, serotonin, melatonin, and pituitary hormones in schizophrenia. Biol Psychiatry 35(3):151–163

    PubMed  Article  CAS  Google Scholar 

  62. Raskind MA, Burke BL, Crites NJ, Tapp AM, Rasmussen DD (2007) Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats. Neuropsychopharmacology 32(2):284–288

    PubMed  Article  CAS  Google Scholar 

  63. Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, Di Nicola M, Grilli A (2011) Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 25:12–13

    Google Scholar 

  64. Rennie K, De Butte M, Pappas BA (2009) Melatonin promotes neurogenesis in dentate gyrus in the pinealectomized rat. J Pineal Res 47(4):313–317

    PubMed  Article  CAS  Google Scholar 

  65. Reynolds RM, Walker BR, Phillips DI, Dennison EM, Fraser R, Mackenzie SM, Davies E, Connell JM (2009) Programming of hypertension: associations of plasma aldosterone in adult men and women with birthweight, cortisol, and blood pressure. Hypertension 53(6):932–936

    PubMed  Article  CAS  Google Scholar 

  66. Rimmele U, Spillmann M, Bärtschi C, Wolf OT, Weber CS, Ehlert U, Wirtz PH (2009) Melatonin improves memory acquisition under stress independent of stress hormone release. Psychopharmacology (Berl) 202(4):663–672

    Article  CAS  Google Scholar 

  67. Sandyk R, Kay SR (1991) The relationship of pineal calcification to cortical atrophy in schizophrenia. Int J Neurosci 57(3–4):179–191

    PubMed  Article  CAS  Google Scholar 

  68. Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, Scherrer U, Duplain H (2009) Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology 150(12):5311–5317

    PubMed  Article  CAS  Google Scholar 

  69. Schneider B, Weber B, Frensch A, Stein J, Fritz J (2000) Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm 107(7):839–842

    PubMed  Article  CAS  Google Scholar 

  70. Shamir E, Barak Y, Plopsky I, Zisapel N, Elizur A, Weizman A (2000) Is melatonin treatment effective for tardive dyskinesia? J Clin Psychiatry 61(8):556–558

    PubMed  Article  CAS  Google Scholar 

  71. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, Elizur A, Weizman R (2001) Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 58(11):1049–1052

    PubMed  Article  CAS  Google Scholar 

  72. Shieh JM (2009) Melatonin ameliorates high fat diet-induced diabetes and stimulates glycogen synthesis via a PKCzeta-Akt-GSK-3b pathway in hepatic cells. J Pineal Res 47(4):339–344

    PubMed  Article  CAS  Google Scholar 

  73. Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, Shenkman L (2000) Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int 17(1):71–76

    PubMed  Article  CAS  Google Scholar 

  74. Suresh Kumar PN, Andrade C, Bhakta SG, Singh NM (2007) Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 68(2):237–241

    Google Scholar 

  75. Tajes M, Gutierrez-Cuesta J, Ortuño-Sahagun D, Camins A, Pallàs M (2009) Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J Pineal Res 47(3):228–237

    PubMed  Article  CAS  Google Scholar 

  76. Tardieu S, Micallef J, Gentile S, Blin O (2003) Weight gain profiles of new anti-psychotics: public health consequences. Obes Rev 4(3):129–138

    PubMed  Article  CAS  Google Scholar 

  77. Utsunomiya K, Shinkai T, Sakata S, Yamada K, Chen HI, De Luca V, Hwang R, Ohmori O, Nakamura J (2012) Genetic association between the dopamine D3 receptor gene polymorphism (Ser9Gly) and tardive dyskinesia in patients with schizophrenia: a reevaluation in East Asian populations. Neurosci Lett 507(1):52–56

    PubMed  Article  CAS  Google Scholar 

  78. VIgano D, Lissoni P, Rovelli F, Roselli MG, Malugani F, Gavazzeni C, Conti A, Maestroni G (2001) A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Neuro Endocrinol Lett 22(2):137–141

    PubMed  CAS  Google Scholar 

  79. Wang F, Fan H, Sun H, Yang F, Luo Y, Liu H, Kosten TR, Lu L, Zhang XY (2012) Association between TNF-α promoter -308A/G polymorphism and tardive dyskinesiain Chinese Han patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 37(1):106–110

    Google Scholar 

  80. Wareski P, Vaarmann A, Choubey V, Safiulina D, Liiv J, Kuum M, Kaasik A (2009) PGC-1alpha and PGC-1beta regulate mitochondrial density in neurons. J Biol Chem 284(32):21379–21385

    PubMed  Article  CAS  Google Scholar 

  81. Watson PE, McDonald BW (2007) Seasonal variation of nutrient intake in pregnancy: effects on infant measures and possible influence on diseases related to season of birth. Eur J Clin Nutr 61(11):1271–1280

    PubMed  Article  CAS  Google Scholar 

  82. Wulff K, Dijk DJ, Middleton B, Foster RG, Joyce EM (2012) Sleep and circadian rhythm disruption in schizophrenia. Br J Psychiatry 200(4):308–316

    Google Scholar 

  83. Zhang L, Su P, Xu C, Chen C, Liang A, Du K, Peng Y, Huang D (2010) Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARγ expression and enhancing Runx2 expression. J Pineal Res 49(4):364–372

    PubMed  Article  CAS  Google Scholar 

  84. Zhou R, Gray NA, Yuan P, Li X, Chen J, Chen G, Damschroder-Williams P, Du J, Zhang L, Manji HK (2005) The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers. J Neurosci 25(18):4493–4502

    PubMed  Article  CAS  Google Scholar 

  85. Zmarowski A, Wu HQ, Brooks JM, Potter MC, Pellicciari R, Schwarcz R, Bruno JP (2009) Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur J Neurosci 29(3):529–538

    PubMed  Article  CAS  Google Scholar 

Download references

Declaration of financial interests

None.

Author information

Affiliations

Authors

Corresponding author

Correspondence to George Anderson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Anderson, G., Maes, M. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Metab Brain Dis 27, 113–119 (2012). https://doi.org/10.1007/s11011-012-9307-9

Download citation

Keywords

  • Melatonin
  • Schizophrenia
  • Anti-psychotics
  • Metabolic
  • Inflammation
  • Vitamin D